Kodiak Sciences, a Phase 1 biotech developing antibody therapies to treat age-related macular degeneration, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Palo Alto, CA-based company was founded in 2009 and plans to list on the Nasdaq under the symbol KOD. Kodiak Sciences filed confidentially on February 14, 2018. Morgan Stanley and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Macular degeneration biotech Kodiak Sciences files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital’s web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital’s research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital’s Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.